Fiche centre
Pratia MCM Krakow
Krakow — Poland
Essais liés17clinical trials
VilleKrakowlocalisation
PaysPolandlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06798896
Essais cliniques associés
17| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Adagrasib | Cancer | Phase 2/3 | NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | RECRUITING |
| Vicadrostat | Insuffisance cardiaque | Phase 3 | NCT06424288 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | RECRUITING |
| Vicadrostat | Insuffisance cardiaque | Phase 3 | NCT06935370 | A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | RECRUITING |
| Epcoritamab | SEP | Phase 2 | NCT05660967 | EPCORE DLBCL-3 — Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | TERMINATED |
| Arm A: Gedatolisib + Palbociclib + Fulvestrant | Cancer | Phase 3 | NCT06757634 | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | RECRUITING |
| SPN-817 | Épilepsie | Phase 2 | NCT06798896 | RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures | RECRUITING |
| Tacabrutideg | Cancer | Phase 3 | NCT06846671 | CaDAnCe-302 — A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | RECRUITING |
| Sonrotoclax | Cancer | Phase 3 | NCT07277231 | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia | RECRUITING |
| BMS-986368 | Myopathies | Phase 2 | NCT06782490 | MSS — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | RECRUITING |
| BHV-7000 | Épilepsie | Phase 2/3 | NCT06132893 | RISE 2 — A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | ACTIVE_NOT_RECRUITING |
| Litifilimab | Lupus | Phase 3 | NCT05352919 | EMERALD — A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION |
| Rimegepant 75mg daily dosing | Migraine | Phase 4 | NCT05217927 | Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens | COMPLETED |
| Lu AG09222 | Migraine | Phase 2 | NCT06323928 | PROCEED — A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments | COMPLETED |
| BHV-7000 | Épilepsie | Phase 2/3 | NCT06309966 | RISE 3 — Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | ACTIVE_NOT_RECRUITING |
| Botulinum toxin type A | Migraine | Phase 3 | NCT06047457 | E-BEOND — A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults | ACTIVE_NOT_RECRUITING |
| Botulinum toxin type A | Migraine | Phase 3 | NCT06047444 | C-BEOND — A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults | ACTIVE_NOT_RECRUITING |
| Pirepemat | Parkinson | Phase 2 | NCT05258071 | A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD) | COMPLETED |